Skip to main content

EDITORIAL article

Front. Genet.
Sec. Neurogenomics
Volume 15 - 2024 | doi: 10.3389/fgene.2024.1520148
This article is part of the Research Topic Multiomics Deciphers the Pathogenesis of Nervous System Diseases and Potential Therapeutic Drugs View all 6 articles

Editorial: Multi-omic Approaches Decipher the Pathogenesis of Nervous System Diseases and Identify Potential Therapeutic Drugs

Provisionally accepted
  • 1 Retired, University of South Carolina, United States
  • 2 Thompson Rivers University, Kamloops, British Columbia, Canada
  • 3 Greater Bay Area Institute of Precision Medicine, Fudan University, China, Guangzhou, China
  • 4 Ludmer Centre for Neuroinformatics and Mental Health, School of Biomedical Sciences, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada
  • 5 The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus

The final, formatted version of the article will be published soon.

    Diseases of the nervous system (both central and peripheral) involve complex underlying molecular mechanisms and have a detrimental impact on the survival and quality of patient life. Multi-omic approaches provide powerful tools for uncovering complex networks of disease pathogenesis and enable the screening of key potential biomarkers and therapeutic drug targets. The term "omics", proposed four decades ago, denotes a discipline within the biological sciences that features the employment of high-throughput technologies to study biomolecules systematically. It includes, but is not limited to, application to the genome, proteome, transcriptome, and metabolome (Vailati-Riboni et al. 2017). These various -omics technologies have revolutionized biomedical research, and in combination, they will no doubt lead to a further understanding of the pathologies of the nervous system. To encourage the scientific community to employ multi-omic approaches in studies of nervous system pathology, we selected a collection of several outstanding research articles that serve as ideal examples.This collection includes studies in murine models for mechanical allodynia in type 1 diabetes (Chen et al. 2023), temporal lobe epilepsy (Huang et al. 2023), pathological anxiety (Gigliotta et al. 2023), and retinal myopia (Pan et al. 2023). Furthermore, we included a clinical study of a molecular diagnosis for episodic ataxia (Audet et al. 2023). Altogether, these studies utilized various types of "-omics" data and bioinformatic techniques to predict genetic biomarkers of disease and potential targets for drug treatment, thereby bridging the translational gap between the basic sciences and clinical applicability.In the first article, Chen et al. (2023) investigated in rat models of type 1 diabetes the pathogenic cause of mechanical allodynia, i.e., pain evoked by light touch, a leading clinical symptom of painful diabetic peripheral neuropathy. Their study associated allodynia with a disorder of lipid metabolism, resulting in lipid accumulation and myelin sheath degeneration. In particular, correlations in the lipidome and transcriptome led to the identification of the downregulation of the gene CYP1A2 (cytochrome P450 1A2) as a putative cause of the disorder, a potential target for clinical research and was consequently validated by immunofluorescence staining and electron microscopy.In another study that relies on a rodent model system, Huang et al. (2023) explored the causes of acute temporal lobe epilepsy (a disorder that is difficult to diagnose) in a mouse epileptic model. They extracted data from the transcriptome and proteome of brain tissue to identify a set of initial causative candidates, which were further refined by machine learning methods to the three genes Ctla2a, Hapln2, and Pecam1, each with a remarkable predictability for the disorder.The third selection in our collection examined a set of innate and stress-induced anxiety-like behaviors in a mouse model (Gigliotta et al. 2023). This study relied on the analysis of gene expression in the cortico-frontal and hippocampal regions of the brain. Compared with the nonanxious control, the anxious variant showed a pattern of gene expression enriched in inflammation and immunity processes. Moreover, they leveraged specialized databases and methods for the identification of drugs and compounds that are associated with the gene expression signatures, thereby offering a treatment direction for this disorder.For the fourth article, Pan et al. (2023) analyzed A-to-I RNA editing in a mouse variant used in the study of myopia. Through RNA sequencing and its analysis, they identified a large set of these editing events, and their genes associated with "form-deprivation" myopia (retinal). These genes are also reported to vary in their roles across the stages of eye development. Their finding was supported through analysis of protein-protein interaction data and was consistent with previously reported literature.Lastly, Audet et al. (2023) utilized whole genome, transcriptomic, and long-read sequencing for molecular diagnosis of late-onset ataxia. Among the eight patients who initially lacked a molecular-specific diagnosis despite clinical examination, several of them were subsequently diagnosed. Consequently, a set of novel genetic variants were identified, which demonstrates the translational potential of another multi-omics study with application to the clinical setting.These studies of our collection share the use of multi-omic techniques and reliance on bioinformatics for the analysis of large-scale data sets. The statistical power of "big data", and a posteriori analysis by statistical methods coincides with recent innovations in the area of computer science known as deep learning. An example of its innovativeness is seen in Galactica (Taylor et al. 2022), a large language model, which is tailored to the natural sciences and has some capacity to "store, combine and reason about scientific knowledge". The genetic-based studies of our collection are adapted for this deep learning framework and its potential to automate the organization and analysis of large data sets (Fawzi et al. 2022).Looking ahead, there is great promise in these multi-omic approaches and their large-scale data collections, where the data may serve as input to power modern machine learning architectures and systems. In particular, deep learning is continuing to enhance our capability at the genetic

    Keywords: Neurological Disease, Pathogenesis, multiomics, high-throughput sequencing, machine learning

    Received: 30 Oct 2024; Accepted: 14 Nov 2024.

    Copyright: © 2024 Friedman, Mamatjan, Pan, Silveira and Zachariou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Robert Friedman, Retired, University of South Carolina, United States
    Yasin Mamatjan, Thompson Rivers University, Kamloops, V2C 0C8, British Columbia, Canada
    Cuiping Pan, Greater Bay Area Institute of Precision Medicine, Fudan University, China, Guangzhou, China
    Patricia Pelufo Silveira, Ludmer Centre for Neuroinformatics and Mental Health, School of Biomedical Sciences, Faculty of Medicine and Health Sciences, McGill University, Montreal, H3A 2B4, Quebec, Canada
    Margarita Zachariou, The Cyprus Institute of Neurology and Genetics, Nicosia, 23462, Cyprus

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.